Breakthrough bets on life sciences rebound with $430m fundraise
The Tishman Speyer and Bellco Capital JV is back with a second fund in what its CEO called ‘the most compelling investment window in years.’
The Tishman Speyer and Bellco Capital JV is back with a second fund in what its CEO called ‘the most compelling investment window in years.’
Copyright PEI Media
Not for publication, email or dissemination